Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.
2.

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.

Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. Review.

3.

Pharmacogenomics of proton pump inhibitors.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.

Pharmacogenomics. 2004 Mar;5(2):181-202. Review.

PMID:
15016609
4.

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.

PMID:
12121503
5.

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.

Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH.

Am J Gastroenterol. 2006 Jul;101(7):1467-75.

PMID:
16863547
6.

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.

Clin Pharmacol Ther. 2001 Mar;69(3):158-68.

PMID:
11240980
7.

Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.

Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9. Epub 2005 Jun 23.

PMID:
15976989
8.
9.

CYP2C19 genotype and the PPIs--focus on rabeprazole.

Lim PW, Goh KL, Wong BC.

J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S22-8. Review.

PMID:
16359346
10.

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.

Helicobacter. 2008 Dec;13(6):532-41. doi: 10.1111/j.1523-5378.2008.00643.x.

PMID:
19166419
11.

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.

Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H.

Clin Pharmacol Ther. 2002 Oct;72(4):453-60.

PMID:
12386647
12.

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A.

Clin Pharmacol Ther. 2007 Apr;81(4):521-8. Epub 2007 Jan 10.

PMID:
17215846
14.

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.

Furuta T, Sugimoto M, Shirai N.

Mol Diagn Ther. 2012 Aug 1;16(4):223-34. doi: 10.2165/11634960-000000000-00000. Review.

PMID:
22873740
15.
16.
17.

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K.

Pharm Res. 2001 Jun;18(6):721-7.

PMID:
11474773
18.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
19.

Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.

Kawai T, Kawakami K, Mikinori K, Takei K, Itoi T, Moriyasu F, Takagi Y, Aoki T, Watanebe K, Matsumoto Y, Rimbara E, Noguchi N, Sasatsu M.

Hepatogastroenterology. 2007 Mar;54(74):649-54.

PMID:
17523342
20.

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.

Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M.

Eur J Gastroenterol Hepatol. 2003 Jan;15(1):27-33.

PMID:
12544691

Supplemental Content

Support Center